LNTH - Lantheus Holdings Net earnings per share (EPS TTM)

Graphic logo of Lantheus Medical Imaging (LNTH)

Global conflicts and sanctions are limiting the export of sensitive pharmaceuticals from Lantheus Holdings, Inc. (LNTH). The trailing 12-month earnings per share trend demonstrates resilient demand, with the latest value recorded as 4.05. High barriers to entry and unique logistics protect the business, while a productive R&D pipeline in PET diagnostics guarantees the company's long-term dominance in its niche.

LNTH (lantheus.com) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/18/2026

Metric breakdowns and analytics for Lantheus Holdings, Inc. (LNTH)

General company analysis:Lantheus (LNTH)
Mass-produced product of Lantheus Corp

Net income per share (TTM) measures the company's total earnings over the last 12 months distributed per common share, which offsets quarterly volatility and allows for an assessment of real capital efficiency. For Lantheus Holdings, Inc. (LNTH), the trend in rolling annual earnings per share reflects the success of a strategy to reduce dependence on a single oncology drug by expanding its radiopharmaceutical portfolio, confirming the fundamental resilience of its assets.